DrugPatentWatch Database Preview
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9% Drug Profile
see a sample report or, see our see our flat-rate plans
When do Heparin Sodium 12,500 Units In Sodium Chloride 0.9% patents expire, and when can generic versions of Heparin Sodium 12,500 Units In Sodium Chloride 0.9% launch?
The generic ingredient in HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9% is heparin sodium. There are seventy-seven drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the heparin sodium profile page.
Summary for HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Suppliers / Packagers: | 1 |
| Clinical Trials: | 66 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9% at DailyMed |
Pharmacology for HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%
| Ingredient-type | Heparin |
| Drug Class | Anti-coagulant Unfractionated Heparin |
US Patents and Regulatory Information for HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospira | HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9% | heparin sodium | INJECTABLE;INJECTION | 018911-005 | Jan 30, 1985 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Hospira | HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9% | heparin sodium | INJECTABLE;INJECTION | 018916-003 | Jan 31, 1984 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
see a sample report or, see our see our flat-rate plans
